Key Highlights

  • Six months ago Oxford Biomedica plc (LSE: OXB) was the subject of a private-equity approach; today it is a FTSE 250 cell and gene therapy manufacturer digesting a guidance cut and preparing to publish half-year results on 22 September 2026.
  • A walked-away bidder, a reset of near-term expectations and a still-intact Long-term Growth story is the kind of combination that can slip off investors' radar.
  • On 7 August 2026 OXB reported unaudited first-half 2026 revenues of approximately £80m, up 9% year on year, and lowered FY2026 Revenue guidance to £180-200m, with an operating EBITDA Margin now expected to be mid-single-digit excluding one-off costs.
  • In March the company had guided to £220-240m and a margin of around 10%.

Six months ago Oxford Biomedica plc (LSE: OXB) was the subject of a private-equity approach; today it is a FTSE 250 cell and gene therapy manufacturer digesting a guidance cut and preparing to publish half-year results on 22 September 2026. A walked-away bidder, a reset of near-term expectations and a still-intact long-term growth story is the kind of combination that can slip off investors' radar, which is why the question of whether OXB is one of 2026's more overlooked London stories deserves a look. The company, which brands itself simply as OXB, is a pure-play contract development and Manufacturing organisation (CDMO) for viral vectors. The immediate catalyst is the 7 August 2026 trading update, which cut full-year revenue guidance to £180-200m from £220-240m while reporting record new client wins. The interims will show whether that was a timing issue or something more structural.

August trading update: guidance cut but record client wins

On 7 August 2026 OXB reported unaudited first-half 2026 revenues of approximately £80m, up 9% year on year, and lowered FY2026 revenue guidance to £180-200m, with an operating EBITDA margin now expected to be mid-single-digit excluding one-off costs, or low single digits as reported. In March the company had guided to £220-240m and a margin of around 10%. Management blamed two factors: "changes in client ordering behaviour", meaning deferrals on selected programmes driven by client strategy or clinical data, plus "a shift in the procurement strategy and change in approval pathway for a larger client"; and the "later-than-expected operational readiness" of the Durham, North Carolina site after a six-month delay to the integration plan, now said to be back on track with the first GMP run under way. The commercial data pointed the other way. OXB signed 17 new clients in the half, a record and 30% above the whole of FY2025. Its non-risk-adjusted pipeline rose 30% year on year to $713m, and a Commercial Supply Agreement was signed with Bristol Myers Squibb for lentiviral vectors supporting BMS's CAR-T portfolio. The revenue Backlog stood at £193m. Chief executive Dr Frank Mathias said: "While we are updating our FY 2026 guidance to reflect the short-term impact of changes in client ordering behaviour and the phased ramp-up of our Durham, NC site, we remain confident about OXB's future." The update restated a 2030 revenue ambition of around £500m, set out at the 2 June 2026 Capital Markets Event, and a longer-term EBITDA margin target of about 30%.

Business overview: a pure-play viral vector CDMO

OXB has spent three decades developing and manufacturing viral vectors, the delivery vehicles that carry genetic material into cells in gene and CAR-T therapies. Having exited in-house drug development, it describes itself as "a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy", earning fees from process development, GMP manufacturing, procurement and storage, and a shrinking stream of licences and royalties. The group operates from Oxford, sites in France, Bedford in Massachusetts and, since October 2025, an FDA-approved commercial-scale Facility in Durham, North Carolina bought from a Subsidiary of National Resilience for $4.5m (£3.3m). At the end of 2025 it had 986 employees and 48 programmes for 40 clients, of which 40 were pre-clinical or early clinical, five late-stage and three commercial. A July 2026 agreement to provide process development and AAV GMP manufacturing from Durham for Plowshare Therapies, a US rare-disease gene therapy developer, illustrates the model. OXB works across both lentiviral and adeno-associated virus (AAV) platforms, broadening its addressable market.

FY2025 results: revenue up 31%, first positive EBITDA

Preliminary results for the year to 31 December 2025, published on 26 March 2026, showed revenue of £168.7m, up 31% from £128.8m (33% at constant currency). Manufacturing revenue rose 18.6% to £81.1m, development revenue 27.1% to £60.1m, and procurement and storage revenue almost quadrupled to £22.3m. Gross Profit was £66.0m, a 39% margin against 41% a year earlier. Operating EBITDA turned positive at £2.3m (£8.1m at constant currency) from a £15.3m loss in FY2024. The operating loss narrowed to £22.5m from £39.4m, helped by a £9.9m gain on the bargain purchase of Durham, and the loss before tax narrowed to £31.9m from £47.3m. Basic loss per share was 26.92p versus 41.75p. Year-end cash was £96.9m, borrowings £41.5m and net cash £55.4m, up from £20.6m. No Dividend is paid. The August update showed how quickly the Balance Sheet can move: gross cash fell to £75m and net cash to £21m by 30 June 2026, a reduction of roughly £34m in six months.

What could drive the stock next?

The interim results on 22 September 2026 are the obvious near-term event, with attention on first-half EBITDA, cash burn and second-half phasing. Evidence that the "larger client" whose procurement strategy changed has resumed ordering would be significant, as would confirmation that Durham has completed its first GMP runs. Conversion of the $713m pipeline and 17 new clients into contracted orders would rebuild the backlog and underpin the guided 25-30% revenue growth for FY2027. There is also the Takeover angle. EQT's Rule 2.8 statement on 25 February 2026 barred it from returning for six months except in limited circumstances, a period that has now expired. The board had rejected earlier proposals as undervaluing the group. Nothing has been announced since and there is no basis to assume any bidder will return, but the episode demonstrated private-equity interest in the asset.

Risks investors should watch

The August downgrade is the central risk. Guidance has been cut by roughly £40m at the midpoint within five months, and the FY2027 margin target has been softened from "at least 20%" to "at least double digit". Client deferrals in cell and gene therapy are driven by clinical data and funding conditions OXB cannot control, and customer concentration is evident in the disclosure that one larger client's procurement change moved the numbers. Cash is the second concern. Net cash of £21m at the half year, against £41.5m of borrowings at the end of 2025, leaves less headroom if losses persist or Durham takes longer to fill. The group has not signalled a need for new equity, but the trajectory bears monitoring. Execution risk at Durham, a multi-site network across the UK, France and the US, and currency translation add to the list. The group also remains loss-making before tax and pays no dividend.

Outlook

OXB enters the autumn with credible long-term positioning as a two-platform viral vector CDMO, a record of winning new clients and a commercial anchor in BMS, set against a near-term reset that has dented confidence and consumed cash. The 22 September interims need to show that first-half EBITDA and second-half visibility are consistent with the revised £180-200m range and that Durham is delivering. Whether the stock proves overlooked or merely re-rated will depend on converting the expanded pipeline into revenue and margin over the next 12 to 18 months.